Study Group

ANA*

Anti-dsDNA

ASMA

F-actin

anti-TPO

VL patients

1/62

0/62

31/62

46/62

0/62

(n = 62)

(1.6%)

(0%)

(50%)

(74.2%)

(0%)

p =

0.5

0.5

0.00000003

0.0000001

____

PKDL patients

11/31

5/31

13/31

20/31

0/31

(n = 31)

35%

16%

42%

64.5%

____

p =

0.0000001

0.02

0.00000003

0.00000001

____

Apparently Healthy

2/62

1/62

4/62

4/62

0/62

(n = 62)

(3.3%)

(1.7%)

(6.6%)

(6.6%)

_____